)
Listed cannabis company Zelira Therapeutics (ASX: ZLD) has today formed a new Oral Care products subsidiary, tasked with selling a hemp-derived cannabinoid-based toothpaste.
The company plans on launching the toothpaste product in the USA by Q4 2020 in partnership with developer Sprinjene, a manufacturer of vegan, Kosher and Halal oral care products.
The cannabinoid-based product will be manufactured by Health and Natural Beauty USA Corp., a New Jersey based company.
Sprinjene CEO and founder Dr Sayed Ibrahim says the launch of the toothpaste, Zelira's first over-the-counter product, will be a unique offering in the market.
"The Sprinjene team is excited about the partnership with Zelira Therapeutics and we look forward to the impact that our products will have in the oral care market," says Ibrahim.
"Our collaboration to commercialise the most advanced hemp-derived cannabinoid-based oral care products expands our reach into new oral care markets where every person can access the daily benefit of using our products."
Read more: Australia's top 20 cannabis companies
Zelira's entrance into the oral care market is another pivot for the cannabis company which recently announced a new research partnership to develop CBD and hemp products for the treatment of diabetes complications.
In July, Zelira partnered with US-based Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise CBD and hemp products to target symptoms associated with Peripheral Arterial Disease and Diabetic Neuropathies.
Under the agreement, Zelira will grant an exclusive licence to CVSCM to manufacture, sell and otherwise commercialise Zelira's proprietary cannabis-based formulations in the USA.
Zelira will exclusively own all products developed under the agreement, with the licence granted to CVSCM to last five years in the first instance and renewable for additional five-year periods.
The company is also undertaking product development programs targeting specific conditions via its revenue generating HOPE branded cannabis formulations and human clinical trial programs focused on insomnia, autism, and opioid reduction in patients with chronic non-cancer pain.
Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.
Business News Australia
Enjoyed this article?
Don't miss out on the knowledge and insights to be gained from our daily news and features.
Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.
Support independent journalism and stay informed with stories that matter to you.
)
)
)
)
)
